부광약품

003000KOSPI

53.5 / 100

Reference Date: 2026-10-23

Financial Score22.0 / 40

News Sentiment12.5 / 25

Momentum9.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Slightly down 2.2% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Bupyeong Pharmaceutical, established in 1960, is a pharmaceutical manufacturer and distributor specializing in products like Faloba and Dexid. In 2023, it achieved a profit turnaround with consolidated sales of 160.1 billion won and operating profit of 1.6 billion won, marking a 27% sales growth year-on-year.

Number of Employees

650people

Average Salary

62.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

25.20Industry Average 15.001.5Point

1.7x industry avg (risky)

PBR

1.11Industry Average 1.204.0Point

In line with industry avg

ROE

4.25Industry Average 8.002.5Point

Below industry avg

Debt Ratio

5.15Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲26.3% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲439.9% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -3.6% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (4%, downtrend)

Current 3,830Won52-week high 9,60052-week low 3,580

1-month return2.0Point

1m -2.17% (slight drop)

Volume trend6.0Point

Volume surge

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral기업설명회(IR)개최(안내공시)2026-10-15